Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03836261 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT03836261 · ClinicalTrials.gov record · last posted 2024-12-27

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

Study acronym: AMPLIFY
StatusActive, Not Recruiting
PhasePhase 3
Started2019-02-25
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL

Amendment record 58 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 58 times since 2019-02-08; most recent amendment 2024-12-24. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-03-12
Status change Recruiting→Active, Not Recruitingv54
2019-04-22
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT03836261
Lead Sponsor Acerta Pharma BV
Collaborators: AstraZeneca
Conditions Chronic Lymphocytic Leukemia
Enrollment 984 participants
Start Date 2019-02-25
Primary Completion 2027-01-31 (estimated)
Study Completion 2027-01-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-27